IMVT Immunovant

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Investor webcast on Monday, September 9th at 8:00 a.m. ET

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9th at 8:00 a.m. ET to provide an update on its Graves’ Disease (GD) program.

The update will consist of new epidemiologic data characterizing the potentially addressable market, additional results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program in GD.

Webcast Details

The company will host a webcast at 8:00 a.m. ET on Monday, September 9th. Please click to register for the event. The live webcast will also be available under the section of Immunovant’s website. A replay of the event and presentation will be available immediately following the event.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit .

Investor Contact:

Renee Barnett, MBA

Chief Financial Officer

Immunovant, Inc.

Source: Immunovant Inc.



EN
05/09/2024

Underlying

IMVTImmunovant

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunovant

 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Provides Corporate Updates and Reports Financial Results fo...

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuro...

February 6, 2026 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant to Report Financial Results for the Third Quarter Ended Dec...

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this . The presentation and webcast details will also be available under “News & Events” in t...

January 23, 2026 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant Announces Pricing of $550 Million Common Stock Financing Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connectio...

December 11, 2025 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Provides Corporate Updates and Reports Financial Results fo...

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing with potentially registrational studies in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA) and Sjögren’s disease (SjD) remains on trackImmunovant remains on track for the first of the two batocli...

November 10, 2025 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant to Report Financial Results for the Second Quarter Ended Se...

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this . The presentation and webcast details will also be available under “News & Events” in the Investor...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch